Eledon Pharmaceuticals, Inc. antibody for islet rejection

T1D Tech & Daily Management Support
1

Eledon presented some research funded by BT1D last year:

https://ir.eledon.com/news-releases/news-release-details/eledon-reports-preliminary-data-first-six-patients-type-1

>“Breakthrough T1D continues to be encouraged by the data from the investigational use of tegoprubart as a novel immunosuppression alternative to advance islet transplantation,” said Esther Latres, Ph.D., Breakthrough T1D Senior Vice President, Research. “We look forward to continuing to support this promising research and to more data on tegoprubart in islet transplants in the future.”

I’ve mostly been tracking cures that encapsulated islet cells so they couldn’t be re-attacked by our own, clearly very aggressive, immune system. The fact that Eledon have what they say is a relatively mild immunosuppression (like it doesn’t kill our kidneys) is certainly very promising, but where is BT1D taking this?

The encapsulation approach certainly seems workable and, if some way were found to do it, direct implants of insulin injection and BG monitoring (think like a pacemaker) would do it too. All of them have downsides; the cures are worse than the disease.

What happens next?

2

Hi John, great to see you here. I found Project ACT - Breakthrough T1D → Novel way to protect transplanted cells shows promise - Breakthrough T1D

At minimum BT1D invested in Eledon because an immunosuppressant with fewer side effects is better for those who have gotten or are candidates for islet cell transplants. I wonder if the research being done to develop the drug is will also be useful to the researchers working on solutions that don’t require immunosuppressants. Your question is a good one, I’d like to learn more too.